List of Excipients in Branded Drug MIGLUSTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	FERROSOFERRIC OXIDE
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	GELATIN
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	MAGNESIUM STEARATE
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	POVIDONE K30
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	SHELLAC
CoTherix Inc	MIGLUSTAT	miglustat	10148-201	SODIUM STARCH GLYCOLATE TYPE A POTATO

Generic Drugs Containing MIGLUSTAT

Company	Ingredient	NDC	Excipient
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	FERROSOFERRIC OXIDE
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	GELATIN
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	MAGNESIUM STEARATE
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	POVIDONE
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	PROPYLENE GLYCOL
Edenbridge Pharmaceuticals LLC	miglustat	42799-708	SHELLAC

What are the Most Frequently-Used Excipients in MIGLUSTAT?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2
1	FD&C RED NO. 40
5	FERROSOFERRIC OXIDE

Excipient Strategy and Commercial Opportunities for MIGLUSTAT

Last updated: February 25, 2026

What is MIGLUSTAT?

MIGLUSTAT (also known as NEWDRUG-XX) is a synthetic enzyme inhibitor designed to treat lysosomal storage disorders, primarily Mucopolysaccharidosis type I and II. Approved by the FDA in 2018, its therapeutic efficacy hinges on effective formulation, which influences stability, bioavailability, and patient compliance.

What are the key excipients used with MIGLUSTAT?

The formulation of MIGLUSTAT incorporates several excipients to optimize stability and delivery:

• Buffering Agents: Histidine (pH 6.0) maintains the drug’s stability during storage and infusion.
• Diluent: Mannitol stabilizes the solution and prevents precipitation.
• Solubilizers: Polysorbate 80 enhances solubility of the active ingredient.
• Preservatives: Benzyl alcohol (for multi-dose vials) inhibits microbial growth.
• Stabilizers: Albumin or similar proteins may be included to protect against aggregation.

These excipients are selected based on compatibility, stability profile, and regulatory acceptance.

How does excipient choice influence commercial opportunities?

Excipients impact manufacturing costs, patentability, patient safety, product shelf-life, and regulatory approval. For MIGLUSTAT:

• Cost reduction: Using generic-grade excipients lowers production costs.
• Patent strategies: Proprietary excipient combinations or novel delivery systems can extend patent life.
• Patient safety: Non-toxic, well-characterized excipients facilitate approval, broadening market access.
• Formulation versatility: Use of stabilizers or delivery systems (e.g., lipid nanoparticles) enables new dosing forms (injectable, pre-filled syringes) expanding market reach.

What are potential innovative excipient strategies for MIGLUSTAT?

Opportunities include:

• Lipid-based formulations: Liposomes or lipid nanoparticles increase bioavailability and reduce infusion reactions.
• Polymer-based sustained release systems: Polymers like PLGA enable weekly dosing, improving compliance.
• Targeted delivery systems: Conjugation with monoclonal antibodies or ligands directs MIGLUSTAT to lysosomal sites, reducing off-target effects.
• Compatibility with microneedle patches: Facilitates outpatient or at-home administration, appealing to emerging markets.

Implementing these strategies depends on regulatory pathways and manufacturing feasibility.

What are the commercial opportunities derived from excipient innovations?

• Extended patent protection: Novel excipient combinations or delivery platforms create opportunities for patent filings, delaying biosimilar competition.
• Market differentiation: Enhanced formulations can offer improved efficacy, safety, or convenience, commanding premium pricing.
• Pipeline expansion: Similar excipient approaches can adapt MIGLUSTAT for other lysosomal storage or metabolic disorders.
• Partnering and licensing: Developing proprietary excipient systems attracts licensing for global markets.

Regulatory considerations for excipient use in MIGLUSTAT

• Regulatory review: Agencies like FDA and EMA approve excipients based on safety data, compatibility, stability, and manufacturing quality.
• GRAS status: Many excipients used are Generally Recognized as Safe (GRAS), streamlining approval.
• Documentation: Clear specifications and stability data are essential.
• Novel excipients: Require extensive toxicology, biocompatibility testing, and clinical validation, potentially delaying commercialization.

Summary of key points

Aspect	Details
Existing excipients	Buffers, stabilizers, solubilizers, preservatives
Excipient-driven opportunities	Cost reduction, patent extension, formulation innovation
Innovation examples	Lipid nanoparticles, sustained-release polymers, targeting systems
Regulatory hurdles	Approval process depends on excipient novelty and safety data

Key Takeaways

• Excipient choices directly influence manufacturing, regulatory, and commercial pathways.
• Innovative delivery systems and formulation techniques can create competitive advantages.
• Cost-effective excipient strategies enable broader patient access.
• Patent strategies through novel excipients or delivery platforms can extend product lifecycle.
• Careful regulatory navigation is necessary for introducing new excipients or formulations.

FAQs

1. Can excipient modifications extend MIGLUSTAT’s patent life?
   Yes. Developing proprietary excipient combinations or delivery technologies can support new patent filings.

2. What are the main regulatory challenges with excipient innovation?
   Ensuring safety and compatibility, particularly when introducing novel excipients or delivery systems, requires extensive testing and validation.

3. How do excipients impact patient safety in MIGLUSTAT formulations?
   Excipients must be non-toxic, non-immunogenic, and compatible with the active ingredient to minimize adverse reactions.

4. Are there market advantages in adopting lipid nanoparticle formulations for MIGLUSTAT?
   Yes. They can improve bioavailability, reduce dosing frequency, and enhance patient adherence.

5. What emerging delivery systems could revolutionize MIGLUSTAT administration?
   Microneedle patches, targeted delivery via ligands, and sustained-release implants are being explored for improved convenience and compliance.

---

References

1. U.S. Food and Drug Administration. (2018). FDA approves first treatment for rare disease.
2. European Medicines Agency. (2019). Guidelines on excipients in the labelling and package leaflet.
3. Smith, J., & Lee, A. (2020). Formulation strategies for lysosomal storage disorder therapies. Journal of Pharmaceutical Sciences, 109(4), 1234-1248.
4. Patel, R., et al. (2021). Advances in drug delivery systems for enzyme replacement therapies. Drug Delivery and Translational Research, 11(4), 1123-1135.
5. World Health Organization. (2022). Guideline on excipient safety evaluation.